HomeFileStructural heart disease

Structural heart disease

View Category

DAY 2

VIVA Post-Market Study: More Evidence for the Valve-in-Valve Technique

Courtesy of the SBHCI. Bioprosthetic surgically-implanted valves degenerate over time, while patients become too old and are at...
solaci -
Learn More
DAY 2

Mitral Valve Global Registry: transcatheter mitral valve replacement due to native valve disease

Courtesy of the SBHCI. The risk of surgical mitral valve replacement in patients with significant annular calcification is...
solaci -
Learn More
Structural heart disease

Cerebral protection during TAVI still offers weak evidence, but there is hope

Silent ischemic embolic lesions are common after transcatheter aortic valve implantation (TAVI). The use of cerebral protection...
solaci -
Learn More
Structural heart disease

Moderate Aortic Stenosis and Ventricular Dysfunction: Should Valve Replacement Come Sooner?

Ventricular dysfunction and moderate aortic stenosis are more frequent with advancing age and often coexist. Afterload reduction...
solaci -
Learn More
DAY 2

CENTERA: Results of the New Self-Expandable Valve

This new device offers the advantage of a lower frame height, which reduces the chance of coronary...
solaci -
Learn More
Antiplatelet

ARTE: Aspirin or Aspirin and Clopidogrel after TAVR?

Courtesy of SBHCI. This study presented at Euro PCR and simultaneously published by JACC Cardiovascular Interventions poses a...
solaci -
Learn More
Mitral valve

Bad prognosis for post-MitraClip mitral valve stenosis: how do we proceed?

Courtesy of Dr. Carlos Fava The EVEREST II trial showed the MitraClip had similar mortality rate to that...
solaci -
Learn More
DAY 1

REPRISE III: Lotus and CoreValve Compared in High-Risk or Inoperable Patients

The efficacy of transcatheter aortic valve replacement (TAVR) has been well-established. However, its limitations include suboptimal deployment...
solaci -
Learn More